Tirofiban After Tenecteplase in Stroke
Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.
By
Kathryn Wighton
May 14, 2026
Clinical Scorecard: Tirofiban After Tenecteplase in Stroke
At a Glance
Category Detail
Condition Key Mechanisms Target Population Patients with acute ischemic stroke without large- or medium-vessel occlusion or cardioembolic source; excluded those with intracranial hemorrhage. Care Setting
Key Highlights
Guideline-Based Recommendations
Diagnosis
Management
I n c l u d e d e f i n i t i o n o f ' i n a d e q u a t e c l i n i c a l r e s p o n s e ' a s n o m e a n i n g f u l N I H S S s c o r e c h a n g e . Monitoring & Follow-up
Risks
Patient & Prescribing Data
Tirofiban is off-label for acute ischemic stroke but shows promise as adjunctive therapy; context on its use in myocardial infarction.
Clinical Best Practices
Related Resources & Content
